Lexicon Pharmaceuticals Inc (LXRX)

[BooDog]

“We will provide further information regarding the close-out of the studies on our first quarter results conference call in early May. Pending review of the data, we expect that we will have accrued sufficient exposure data and cardiovascular events to satisfy all requirements for type 2 diabetes and, even with the early close-out, that these studies will contribute scientifically important data in the areas of cardiovascular and chronic kidney disease. Importantly, this shift allows us to conserve our financial resources and to prioritize our portfolio to advance pipeline initiatives such as telotristat ethyl in biliary tract cancer and LX9211 in neuropathic pain.”

http://www.lexpharma.com/media-center/news/740-lexicon-pharmaceuticals-provides-an-update-on-the-sotagliflozin-type-2-diabetes-program

COVID-19 is likely messing with many many companies trials.

Roll with it or not.